Early effects of low molecular weight heparin therapy with soft-mist inhaler for COVID-19-induced hypoxemia: a phase iib trial
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
MDPI
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
In COVID-19-induced acute respiratory distress syndrome, the lungs are incapable of filling with sufficient air, leading to hypoxemia that results in high mortality among hospitalized patients. In clinical trials, low-molecular-weight heparin was administered via a specially designed soft-mist inhaler device in an investigator initiated, single-center, open-label, phase-IIb clinical trial. Patients with evidently worse clinical presentations were classed as the “Device Group”; 40 patients were given low-molecular-weight heparin via a soft mist inhaler at a dose of 4000 IU per administration, twice a day. The Control Group, also made up of 40 patients, received the standard therapy. The predetermined severity of hypoxemia and the peripheral oxygen saturation of patients were measured on the 1st and 10th days of treatment. The improvement was particularly striking in cases of severe hypoxemia. In the 10-day treatment, low-molecular-weight heparin was shown to significantly improve breathing capability when delivered via a soft-mist inhaler. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Açıklama
Anahtar Kelimeler
Anti-coagulan, COVID-19, Low-Molecular-Weight Heparin, Pulmonary, Soft-mist İnhaler
Kaynak
Pharmaceutics
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
13
Sayı
11
Künye
Erelel M, Kaskal M, Akbal-Dagistan O, Issever H, Dagistanli AS, Balkanci H, Oguz MS, Qarayeva A, Culha M, Erturk A, Basarir NS, Sahin G, Uresin AY, Araman AO, Medetalibeyoglu A, Tukek T, Oncul MO, Yildiz-Pekoz A. Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial. Pharmaceutics. 2021; 13(11):1768. https://doi.org/10.3390/pharmaceutics13111768
